Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

BACKGROUND: The majority of urothelial cancers (UC) harbor alterations in retinoblastoma (Rb) pathway genes that can lead to loss of Rb tumour suppressor function. Palbociclib is an oral, selective inhibitor of CDK 4/6 that restores Rb function and promotes cell cycle arrest. METHODS: In this phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Rose, Tracy L., Chism, David D., Alva, Ajjai S., Deal, Allison M., Maygarden, Susan J., Whang, Young E., Kardos, Jordan, Drier, Anthony, Basch, Ethan, Godley, Paul A., Dunn, Mary W., Kim, William Y., Milowsky, Matthew I.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6189143/
https://ncbi.nlm.nih.gov/pubmed/30293995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0229-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados